Sublingual Immunotherapy
Publication Date: May 1, 2017
Key Points
Key Points
- It is crucial that the practicing allergist separate the data on FDA reviewed products that have led to approval of these products (ie, dust mites, grass and ragweed tablets) from the data in the literature with other allergens and other formulations (eg, liquid formulations) that have not undergone the rigor of FDA review.
Diagnosis
...iagnosis
...Allergy Organization Grading System for Sublin...
...e 2. Description of Local Adverse Effects...
Treatment
...eatment...
...se only FDA-approved SLIT products...
...sician should be aware that SLIT may not be...
...proved SLIT products very cautiously in the pre...
...o not assume dosing equivalence betwe...
...ister the patient’s first dose of SLIT in a m...
...scribe epinephrine (either an autoinjector o...
...ent’s SLIT dose if they have missed treat...
...dule patients receiving SLIT therapy for regular...
...ts for SLIT in the United States are the 5-grass...
...able 3. Suggested Guidelines for the Practicin...
...able 4. FDA-Approved Sublingual TabletsHav...